The physician has a unique perspective that non-clinical investors don’t: they know firsthand whether a technology will be adopted. They deeply understand if it truly is better for them and their patients.
A new EU Commission study on the Deployment of AI in Healthcare makes one thing crystal clear: AI isn’t just a buzzword, it could be the lifeline our systems desperately need.
Originally CE marked in 2021 for limited to high-risk patients only, .Abbott has now received CE mark approval for its Navitor transcatheter aortic valve replacement (TAVR) system to treat low- and intermediate-risk patients with symptomatic, severe aortic stenosis.
Company says the system empowers clinical teams to respond to surges, track usage and ease workflows with user-friendly touchscreen technology for telemetry patients on the move.
The Globe System, according to the company, achieves highly durable lesions and an excellent safety profile, together with integrated high-density mapping and true single-shot PVI for treatment of atrial fibrillation.
The rise of AI-powered health apps that claim to diagnose conditions in real time is transforming how we approach healthcare. From symptom checkers to wearable ECG monitors and AI stethoscope apps, these tools promise early diagnoses and personalized healthcare at our fingertips. What if they go wrong?
A comprehensive update on the combination products market shows significant industry partnerships, development challenges, and strategic imperatives for success in the sector characterized by dynamic collaboration between pharmaceutical and device companies, rapid product development cycles, and complex regulatory landscapes.